Effects of cyclandelate on diabetic peripheral neuropathy

N. Canal, G. Comi, P. Marchettini, G. Pozza

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The role of aldose reductase in the development of peripheral neuropathy as a late complication of diabetes is discussed and preliminary results of a double blind trial of cyclandelate and placebo in the treatment of diabetic peripheral neuropathy are presented. Examination of the data from the first 16 patients who have completed the study indicates improvement in nerve conductance in the cyclandelate treated group. The possible explanation for the improvement is discussed. Definite conclusions regarding the value of cyclandelate in the treatment of diabetic peripheral neuropathy will have to await the completion of the study.

Original languageEnglish
Pages (from-to)62-68
Number of pages7
JournalBritish Journal of Clinical Practice
Volume38
Issue number6 SUPPL. 34
Publication statusPublished - 1984

Fingerprint

Cyclandelate
Diabetic Neuropathies
Peripheral Nervous System Diseases
Aldehyde Reductase
Diabetes Complications
Placebos
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Canal, N., Comi, G., Marchettini, P., & Pozza, G. (1984). Effects of cyclandelate on diabetic peripheral neuropathy. British Journal of Clinical Practice, 38(6 SUPPL. 34), 62-68.

Effects of cyclandelate on diabetic peripheral neuropathy. / Canal, N.; Comi, G.; Marchettini, P.; Pozza, G.

In: British Journal of Clinical Practice, Vol. 38, No. 6 SUPPL. 34, 1984, p. 62-68.

Research output: Contribution to journalArticle

Canal, N, Comi, G, Marchettini, P & Pozza, G 1984, 'Effects of cyclandelate on diabetic peripheral neuropathy', British Journal of Clinical Practice, vol. 38, no. 6 SUPPL. 34, pp. 62-68.
Canal, N. ; Comi, G. ; Marchettini, P. ; Pozza, G. / Effects of cyclandelate on diabetic peripheral neuropathy. In: British Journal of Clinical Practice. 1984 ; Vol. 38, No. 6 SUPPL. 34. pp. 62-68.
@article{8e10956041084652b7467c0626a917e3,
title = "Effects of cyclandelate on diabetic peripheral neuropathy",
abstract = "The role of aldose reductase in the development of peripheral neuropathy as a late complication of diabetes is discussed and preliminary results of a double blind trial of cyclandelate and placebo in the treatment of diabetic peripheral neuropathy are presented. Examination of the data from the first 16 patients who have completed the study indicates improvement in nerve conductance in the cyclandelate treated group. The possible explanation for the improvement is discussed. Definite conclusions regarding the value of cyclandelate in the treatment of diabetic peripheral neuropathy will have to await the completion of the study.",
author = "N. Canal and G. Comi and P. Marchettini and G. Pozza",
year = "1984",
language = "English",
volume = "38",
pages = "62--68",
journal = "British Journal of Clinical Practice",
issn = "0007-0947",
publisher = "Medicom International, Inc.",
number = "6 SUPPL. 34",

}

TY - JOUR

T1 - Effects of cyclandelate on diabetic peripheral neuropathy

AU - Canal, N.

AU - Comi, G.

AU - Marchettini, P.

AU - Pozza, G.

PY - 1984

Y1 - 1984

N2 - The role of aldose reductase in the development of peripheral neuropathy as a late complication of diabetes is discussed and preliminary results of a double blind trial of cyclandelate and placebo in the treatment of diabetic peripheral neuropathy are presented. Examination of the data from the first 16 patients who have completed the study indicates improvement in nerve conductance in the cyclandelate treated group. The possible explanation for the improvement is discussed. Definite conclusions regarding the value of cyclandelate in the treatment of diabetic peripheral neuropathy will have to await the completion of the study.

AB - The role of aldose reductase in the development of peripheral neuropathy as a late complication of diabetes is discussed and preliminary results of a double blind trial of cyclandelate and placebo in the treatment of diabetic peripheral neuropathy are presented. Examination of the data from the first 16 patients who have completed the study indicates improvement in nerve conductance in the cyclandelate treated group. The possible explanation for the improvement is discussed. Definite conclusions regarding the value of cyclandelate in the treatment of diabetic peripheral neuropathy will have to await the completion of the study.

UR - http://www.scopus.com/inward/record.url?scp=0021246865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021246865&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 62

EP - 68

JO - British Journal of Clinical Practice

JF - British Journal of Clinical Practice

SN - 0007-0947

IS - 6 SUPPL. 34

ER -